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Necrotizing fasciitis (NF) is a severe, rare, potentially lethal soft tissue infection that devel-
ops in the scrotum and perineum, the abdominal wall, or the extremities. The infection
progresses rapidly, and septic shock may ensue; hence, the mortality rate is high (median
mortality 32.2%). Prognosis becomes poorer in the presence of co-morbidities, such as
diabetes mellitus, immunosuppression, chronic alcohol disease, chronic renal failure, and
liver cirrhosis. NF is classified into four types, depending on microbiological findings. Most
cases are polymicrobial, classed as type I. The clinical status of the patient varies from
erythema, swelling, and tenderness in the early stage to skin ischemia with blisters and
bullae in the advanced stage of infection. In its fulminant form, the patient is critically ill with
signs and symptoms of severe septic shock and multiple organ dysfunction. The clinical
condition is the most important clue for diagnosis. However, in equivocal cases, the diag-
nosis and severity of the infection can be secured with laboratory-based scoring systems,
such as the laboratory risk indicator for necrotizing fasciitis score or Fournier’s gangrene
severity index score, especially in regard to Fournier’s gangrene. Computed tomography or
ultrasonography can be helpful, but definitive diagnosis is attained by exploratory surgery
at the infected sites. Management of the infection begins with broad-spectrum antibiotics,
but early and aggressive drainage and meticulous debridement constitute the mainstay
of treatment. Postoperative management of the surgical wound is also important for the
patient’s survival, along with proper nutrition. The vacuum-assisted closure system has
proved to be helpful in wound management, with its combined benefits of continuous
cleansing of the wound and the formation of granulation tissue.
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INTRODUCTION
The term necrotizing fasciitis (NF) describes a group of relatively
uncommon, but life-threatening infections of the skin, soft tis-
sues, and muscles, which tend to progress rapidly through the
fascia planes, causing gradual destruction of the fascia at a rate
reaching 2–3 cm/h. Developing in the lower or upper extremities,
the perineum and genital area (Fournier’s gangrene) and in the
abdominal wall, its swift clinical course is correlated with polymi-
crobial infection and synergy, which usually co-exists (1, 2). The
majority of cases present anaerobic bacteria that proliferate in a
hypoxic environment and produce gas, which accumulates in the
soft tissue spaces, giving the characteristic image of gas gangrene
on plain X-rays and computed tomography (CT) scans (3).
Early diagnosis of NF is mandatory. Any delay could prove
fatal, given its association with more extensive surgery, higher
rates of amputation, and higher mortality rates. Furthermore, if
left untreated, the infection could lead to systemic inflammatory
response syndrome (SIRS).
Necrotizing fasciitis was first recognized in 500 BC, when
Hippocrates reported a clinical description of a complication of
erysipelas disease, resembling the current description of NF (4).
In France, Claude Colles, chief surgeon of the Hotel Dieu in Lyon,
described a condition in 1783 that was very similar to modern
descriptions of NF (5). The first description of “modern” NF was
made by Joseph Jones, a military surgeon of the army of the Con-
federate States of America. In 1871, he reported 2,642 cases of gas
gangrene treated in hospital during the American Civil War, with
a mortality rate of approximately 46% (6). In 1883, Jean Alfred
Fournier described a syndrome with necrosis of the perineum in
five men; this type of NF was subsequently given his name and is
known as Fournier’s gangrene (7). In 1924, Meleney reported an
association with beta-hemolytic streptococcus A in a study of a
series of hospitalized cases in Beijing. Thereafter, these cases were
described for several decades as Meleney’s gangrene (8). In 1952,
the term “necrotizing fasciitis” was proposed by Wilson, as a more
accurate description of this disease (9). The late 1980s witnessed a
renewed interest in this pathology. Stevens reported that, among
20 patients who presented with streptococcal shock, 11 were diag-
nosed as having NF. The disease was popularized by the media as
“flesh-eating bacteria syndrome” (10).
EPIDEMIOLOGY
The annual incidence of NF is estimated at 500–1,000 cases annu-
ally, and its prevalence globally has been reported to be 0.40 cases
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per 100,000 population (11). It is seen to have a predilection
for men, with a male-to-female ratio of 3:1; this ratio is mainly
correlated with the increased incidence of Fournier’s gangrene in
men. The disease affects all age groups, although middle-aged and
elderly patients (over 50 years of age) are more likely to be infected
(1). The median mortality ratio of NF is a controversial issue. In
their review of the literature, Goh et al. concluded that the median
mortality ratio was 21.5% (12). However, its range in the litera-
ture is extensive, varying from 8.7 to 76% (13). In regard to NF
of the extremities, the mortality rate is slightly lower than that
recorded for abdominal and perineal infections (14, 15). Patients
with Fournier’s gangrene that has not spread to the abdominal
wall tend to have a better survival. As a general rule, without treat-
ment, the mortality rate approaches 100%. Anaya et al. (16) have
demonstrated that infection of the lower extremities is the most
common site of NF (57, 8%), followed by the abdomen and the
perineum. NF of the upper limbs is rare compared to that of the
lower limbs (17).
ETIOLOGY
Trauma is the most common identifiable etiology. The majority
of patients have a history of minor or major traumas, gener-
ally involving external injuries and surgical wounds. Appendicitis
with perforation, infection following the repair of an incarcerated
hernia, perforated diverticulitis, necrotic cholecystitis, gastroduo-
denal perforation, small bowel perforation, and obstructive colon
cancer with perforation rank among the most frequent causes
of complicated intra-abdominal infections that can lead to NF.
Notably, the incidence of NF resulting from a surgical wound in
the chest wall is greater than that recorded from analogous wounds
in the lower abdominal wall. Such cases present a high risk of
osteomyelitis, which substantially increases the mortality of these
patients.
Fournier’s gangrene is often the result of surgical wounds, skin
abscess drainage,and pressure sores. It can also present as a compli-
cation of colorectal disease due to anorectal infection, ischiorectal
abscesses, and colon perforations. Other causes include a possible
urethral stricture and a trauma from an indwelling Foley catheter.
In women, it has commonly been ascribed to Bartholin abscesses
or vulval skin infections.
In Asia, consumption of raw or undercooked seafood or injury
by fish fins can lead to NF (12). In this group of infections,
bacteria such as Vibrio spp., Aeromonas spp., and Shewanella
spp. are commonly involved and are usually known as “marine
bacteria” (18).
CO-MORBIDITIES AND RISK FACTORS
The most frequent co-morbidity in patients with NF is diabetes
mellitus. The prevalence of diabetes mellitus in patients with any
type of NF ranges between 40 and 60% (12, 19). Other common
co-morbidities include liver cirrhosis, chronic heart failure, obe-
sity, alcohol abuse, immunodeficiency, systemic lupus erythemato-
sus, Addison’s disease, pre-existing hypertension, and peripheral
vascular disease (20, 21). A septic condition and hypotension at the
time of admission are significant predicting factors for mortality
and outcome. Chronic renal failure is another indisputable pre-
disposing factor for higher mortality in patients with NF. Elevated
serum creatinine, along with elevated blood urea, is also strongly
associated with higher mortality rates (22).
The use of non-steroidal anti-inflammatory drugs (NSAIDs) or
steroid drugs can suppress fever, thereby hampering the diagno-
sis of NF (8). Furthermore, Martinschek et al. have demonstrated
that an increase of serum creatine kinase and lactate parameters, as
well as a decrease of serum antithrombin III, proved by a low INR,
are significant parameters for an unfavorable outcome, particu-
larly in regard to Fournier’s gangrene (20). Other risk factors, such
as systemic acidosis, low hematocrit, and albumin levels, are also
strongly linked with a high mortality, while concomitant condi-
tions increase the mortality rate further (23). Patients displaying
accompanying diseases are usually characterized as critically ill
and require prolonged intensive care. Diabetes, in particular, is a
disease, which often combines many of the above co-morbidities,
and is hence susceptible to the development of NF (24). However,
the presence of diabetes mellitus has not been proven to affect
mortality (25).
Advanced age constitutes another risk factor for higher inci-
dence and mortality, although somewhat controversial. Large
population-based studies have shown that advanced age is a strong,
independent predictor of mortality (26). A study by Rea and
Wyrick reported a mortality rate of 67% in patients over 50 years
of age and 4% in patients under that age (27). Other studies have
concurred that advanced age is a risk factor for higher mortality,
but only when accompanied by other risk factors such as renal
failure, or delayed surgical debridement (24). This combination
is also associated with advanced disease and a more fulminant
infection.
Whether or not patients with NF show a gender predilection
with regard to mortality is also a topic of debate. Fournier’s gan-
grene shows male predominance with a reported rate of 96% (28).
Czymek et al. found that mortality was significantly higher among
females (50% F vs. 7.7% M) (29). However, studies involving a
larger study population have concluded that there is no statistical
correlation between female gender and increased mortality (30).
The extension and variability of infection are assumed to
increase mortality. NF can affect an entire extremity within 24 h
(31), but it can also show slow progression over a period of sev-
eral weeks. In some patients, the disease remains dormant and
unexpectedly spreads rapidly without any readily apparent reason
(24). The factors that lead to the fulminant form of NF, with a
potentially lethal outcome within 24 h, remain unidentified (32).
Some studies indicate that the spread of gangrene does not relate
to a poorer prognosis. Notwithstanding, the extension of gangrene
to the abdominal wall has been reported to be directly related to
increased mortality (33).
PATHOPHYSIOLOGY
Infection begins in the hypodermis or the superficial fascia, as the
more superficial layers (dermis and epidermis) are not affected at
the beginning (34). The synergistic action of the virulence fac-
tors of bacteria and the specific factors of the host are implicated
in the development of NF. The extension of the infection and
necrosis is facilitated by the synergy between the different bacte-
ria and toxins and the enzymes they produce (35). An anaerobic
environment promotes growth of anaerobic bacteria. Necrosis of
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the hypodermis and superficial fascia is directly related to bacterial
enzymes that destroy the fascia and fat, and secondarily to vascular
origin. Invasive bacteria cause thrombosis of the nutrient vessels,
which are located in the hypodermis, leading to tissue ischemia
aggravated by the presence of edema. Tissue ischemia promotes
infectious dissemination leading to skin necrosis at a later stage.
It also explains the intense pain phenomena that are usually
observed, especially when the nerve branches are also affected.
Such cases also display signs of regional hypoesthesia/anesthesia.
The fascial and hypodermic necrotic spread is greater than the
overlying skin changes. Lymphangitis and lymphadenopathy are
rare due to thrombosis of the vessels. Gas formed by anaerobic
bacteria may lead to crepitus.
MICROBIOLOGY
Recent studies have concluded that NF can be classified into four
types, according to microbiological findings (35)(Table 1). The
most common is type I, also known as the polymicrobial type.
Accounting for 70–90% of cases, it typically affects patients with
several co-morbidities, such as diabetes mellitus. Two or more
pathogens are implicated in this infection (with an average of 4.4
species) and it is mostly found in the trunk and perineum.
Type II, otherwise known as monomicrobial, is defined as
infection with beta-hemolytic Streptococcus A (Streptococcus pyo-
genes). S. pyogenes is commonly found in young and healthy
patients with NF of the extremities. Its pathogenesis is explained
by the several virulence factors produced by this organism (36).
In some cases, the infection can be associated with Staphylococcus
aureus. S. aureus secretes toxins, which cause leukocyte destruction
and tissue necrosis. Found in the fulminant forms of NF, S. aureus
is not easy to manage, especially when the responsible pathogen
is the methicillin-resistant S. aureus (MRSA), which is the case
in 10–30% of all patients. Typically, these infections occur after
small incisions, and appear to be highly correlated with the use
of NSAIDs (37). Specifically observed in patients without serious
co-morbidities, the infection is most often found in the limbs. The
risk of toxic shock syndrome is increased in such cases, and the
outcome is unfavorable.
Type III includes monomicrobial infections involving the
Clostridium species or Gram-negative bacteria. Clostridium
species are anaerobic bacteria that can be produced by external
injuries (deep wound or crush injury causing local devasculariza-
tion) or surgical wounds (intestinal and obstetric). Clostridium
infections are currently more frequent among drug addicts (38),
and C. perfringens is the most common bacterium of the C. species.
Vibrios spp. infections can also lead to type III NF. Vibrio vulnificus
is a marine bacterium frequently isolated in Asia (21). Aeromonas
hydrophila is found in freshwater or low salinity water and in the
soil. The clinical symptoms of infections by these two bacteria are
similar; hemorrhagic blisters, lesions, and purpuric necrosis are
the dominant symptoms, along with the extremely rapid spread
of disease.
Finally, type IV is the result of fungal infections, mainly Can-
dida spp. and Zygomycetes. This type is found mainly in the
immunocompromised host. Infections by these fungi often occur
after trauma; the clinical image is aggressive and rapidly extensive,
particularly in immunocompromised patients.
Microbiological diagnosis is obtained in almost 75% of all cases
of NF (39), and is based on the good quality of the pre- and intra-
operative samples and blood cultures. Blood cultures are positive
in 25% of all cases, while cultures obtained from the site of injury
during surgical debridement result as positive in 80% of cases (40).
DIAGNOSIS
CLINICAL SIGNS AND SYMPTOMS
Patients with NF usually present with the classic triad of symp-
toms: local pain, swelling, and erythema (12). Tachycardia (>100
beats/min) and fever are the most common vital sign abnormali-
ties, followed by hypotension (SAP< 100 mmHg) and tachypnea
(>20/min). These vital sign abnormalities, along with the skin ery-
thema, are most useful in securing the diagnosis of NF from other
soft tissue infections (41). The infected site displays tenderness,
sclerosis, skin necrosis, and hemorrhagic bullae (42).
Depending on the development of the infection, the clini-
cal image described above may not always be evident. Conse-
quently, two groups of symptoms are considered, namely early
and advanced symptoms (43). The most common early signs are
erythema, local warmth, skin sclerosis, and edema. However, in
the fulminant form of disease, the patient is critically ill with signs
and symptoms of severe septic shock and multiple organ dys-
function syndrome, along with extensive necrosis of soft tissue.
In this case, the clinical picture deteriorates rapidly within a few
hours; pain is severe and usually manifests before the cutaneous
signs. Remarkably,pain seems to be disproportionate to the clinical
findings.
In contrast, the subacute form of the disease has a relatively
slow clinical course, which may endure for days or weeks. The
early clinical status of the subacute form is the result of an existing
Table 1 | Classification of responsible pathogens according to type of infection.
Microbiological type Pathogens Site of infection Co-morbidities
Type I (polymicrobial) Obligate and facultative anaerobes Trunk and perineum Diabetes mellitus
Type II (monomicrobial) Beta-hemolytic streptococcus A Limbs
Type III Clostridium species Limbs, trunk, and perineum Trauma
Gram-negative bacteria Seafood consumption (for Aeromonas)
Vibrios spp.
Aeromonas hydrophila
Type IV Candida spp. Limbs, trunk, perineum Immunosuppression
Zygomycetes
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condition leading to infection. The patient often presents with
a skin infection, such as folliculitis or abscess, gangrene on the
extremities, pressure sore(s), or a complicated surgical wound.
Erythema or skin sclerosis is present at the site of infection. The
patient usually feels pain at the site of the injury, and this is a very
strong diagnostic hint. However, local nerves can also be infected,
usually resulting in the partial loss of sensation (44).
As the infection develops, the pain becomes more intense. The
clinical image is characterized by symptoms of general toxicity
including fever, dehydration, confusion, dizziness, diarrhea, nau-
sea, vomiting, weakness, and malaise (19). If the patient remains
undiagnosed or untreated, the clinical status deteriorates rapidly.
The cutaneous symptoms may progress to blisters and bullae, ulti-
mately leading to circumscribed necrosis of the skin. Initially, the
bullae contain serous fluid, but, as the infection progresses, they
may become hemorrhagic. Gas formation can lead to crepitus in
the overlying skin, indicating anaerobic infection, such as C. per-
fringens. This classical skin condition does not normally present
until day five or later (45).
Symptoms of septic shock or MODS frequently appear in the
late phase of its subacute form. As a result, the patient displays
hypotension, elevated white blood cell count, metabolic acido-
sis, coagulopathy, changes in mental status, and weakness. In this
late stage of the disease, the patient looks apathetic and indiffer-
ent. Additional symptoms pertaining to co-morbidities may also
coexist.
The symptoms of disease are not characteristic; hence, it is often
misdiagnosed as cellulitis or abscess. The most consistent feature
of early NF is pain, which is not in proportion to the swelling or
erythema (46). Moreover, as a consequence of the enzymatic and
toxin action, tenderness to palpation extends beyond the area of
apparent involvement, to spread along fascial plains. In addition,
the margins of involvement are usually indistinct, and lymphan-
gitis is rarely present, given that the infection is in the deep fascia
rather than the skin (47).
Cases with upper limb infection do not always present a typ-
ical picture. In this instance, patients may appear systemically
well (21). Another cause that complicates diagnosis is the absence
of fever in most cases. Several drugs, such as NSAIDs, steroids,
and antibiotics can lower body temperature and mask fever. For
that reason, the absence of pyrexia does not necessarily exclude
NF (12, 41).
Fournier’s gangrene has a slightly different clinical course.
It usually begins with pain and itching of the perineum and
scrotal skin. In genitourologic types of Fournier’s gangrene, the
pathogens pass through the Buck’s fascia of the penis and spread
along the Darto’s fascia of the scrotum and penis, Colle’s fas-
cia of the perineum, and Scarpa’s fascia of the lower abdomi-
nal wall (19). Additional necrosis of the superficial fascia and
fat produces a thin watery malodorous fluid and crepitus. Sim-
ilarly, patients may present high fever, anxiety, altered mental
status, leukocytosis, shock, and tachypnea, when shock is about
to develop. Once clinical signs become obvious, the appearance
resembles the late phase of NF, with visible bruising, bullae
and cutaneous necrosis due to the extension of the necrotizing
process.
BEDSIDE AND LABORATORY TESTS
Laboratory results in this disease are not usually specific. However,
certain laboratory findings can help the clinician to differentiate
NF from other skin diseases, such as necrotizing soft tissue infec-
tion. Specifically, leukocytosis is a common feature in patients
with NF (48), and white blood cell count in excess of 20,000/L is
highly suspect. Blood urea nitrogen >18 mg/dL and serum crea-
tinine >1.2 mg/dL reflect ongoing renal failure, which is typically
present in these patients. Serum creatine kinase is also elevated
(CK) in patients with severe sepsis and MODS (48). Majeski et al.
suggested that C-reactive protein >16 mg/dL or creatine kinase
>600 IU/L generally precludes group A β-hemolytic streptococcal
infection (49). However, this recommendation is rarely followed
by clinicians.
Several laboratory-based scoring systems have been proposed
for establishing early diagnosis of NF (50). The Laboratory Risk
Indicator for Necrotizing Fasciitis (LRINEC) proposed by Wong
et al. (51–53) is one such example (Table 2). In addition to
enabling early recognition of the disease, this score can also facil-
itate the classification of patients into risk categories, and help
in the allocation of diagnostic resources. Another scoring system
is the Fournier’s Gangrene Severity Index (FGSI) that has shown
remarkable success in helping to determine whether or not the
patient requires surgical debridement (54).
Bedside tests, imaging tests [CT or magnetic resonance imag-
ing (MRI)], or frozen section biopsy can be carried out in patients
with equivocal clinical findings and a moderate or high risk of
NF based on the LRINEC score (>5). The finger test and frozen
section biopsy are used as complementary diagnostic modalities
in patients with an equivocal diagnosis. Surgical exploration is
regarded as the mainstay for investigation and treatment. The fin-
ger test is a bedside procedure performed under local anesthesia by
which, a 2-cm incision is made down to the deep fascia, at which
level gentle probing of the index finger is applied. The presence
Table 2 | LRINEC scoring system for necrotizing fasciitis.
Variable Score
CRP (mg/L)
>150 4
WBC (g/L)
<15 0
15–25 1
>25 2
Hemoglobin (g/dL)
>13.5 0
11–13.5 1
<11 2
Sodium (mmol/L)
<135 2
Creatinine (µmol/L)
>141 2
Glucose (mmol/L)
<10 1
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of characteristic “dishwater pus,” along with the lack of bleeding
and lack of tissue resistance to blunt finger dissection are positive
findings correlated with NF. Another useful bedside test is an inci-
sional biopsy down to the fascial level with an immediate frozen
section, culture, and Gram stain (55, 56).
The combination of surgical exploration and microbiological
and histopathological analysis of 1 cm3 of soft tissue is consid-
ered the gold standard for confirming diagnosis, when the latter is
ambivalent.
IMAGING TESTS
Imaging investigation can help to establish the diagnosis of NF
especially in equivocal cases. Although plain radiography has low
sensitivity and specificity, it is capable of showing gas formation in
the soft tissue (33), which is present in almost half of all patients,
and it strongly indicates infection by the Clostridium species. CT
and MRI are more sensitive and specific than plain radiography.
A CT scan can show the extent of tissue infection, fascial swelling,
inflammation, and gas formation. An MRI scan provides better
accuracy than CT, though not widely used, due to cost. Ultra-
sonography is also a feasible option, providing useful information
concerning the nature and extent of infection, especially when the
diagnosis is unclear (57). In terms of diagnosis, the most signif-
icant finding is the hyperechoic foci with reverberation artifact
and dirty shadowing at the site of infection (57), representing
the subcutaneous gas. However, ultrasonography requires a highly
skilled operator; this requirement hampers its use in the ICU,
where patients with NF are usually treated.
TREATMENT
ANTIBIOTIC TREATMENT
Since ischemia and hypoxia compromise the adequate delivery
of antibiotics to the infection site, conservative treatment with
antibiotics alone has little value in the management of NF (58).
However, they play a significant role in surgical management
of the infection. Patients should be immediately treated with
broad-spectrum antibiotics, when NF is suspected. The empir-
ical usage of antibiotics is based on the microbiological clas-
sification of NF. Antibiotic treatment of a polymicrobial infec-
tion should be based on history, Gram stain, and culture. Initial
treatment includes ampicillin or ampicillin–sulbactam combined
with metronidazole or clindamycin (59). Anaerobic coverage is
quite important for type 1 infection; metronidazole, clindamycin,
or carbapenems (imipenem) are effective antimicrobials. Broad
gram-negative coverage is necessary as an initial empirical therapy
for patients who have recently been treated with antibiotics, or
been hospitalized. In such cases, antibiotics such as ampicillin–
sulbactam, piperacillin–tazobactam, ticarcillin–clavulanate acid,
third or fourth generation cephalosporins, or carbapenems are
used, and at a higher dosage.
Type 2 disease is treated with antibiotics against S. pyogenes
and S. aureus, which usually coexist with the former. Hence, first
or second generation of cephalosporins are used for the cover-
age of methicillin-sensitive Staphylococcus aureus (MSSA). MRSA
tends to be covered by vancomycin, or daptomycin and linezolid
in cases where S. aureus is resistant to vancomycin. Some stud-
ies suggest that clindamycin is superior to penicillin in managing
streptococcal infections (60), but this has yet to be satisfactorily
proven. Another study has proposed that clinicians should con-
sider adding clindamycin to the beta-lactam antibiotic regimen
when NF or myositis is present (61).
Type 3 NF should be managed with clindamycin and peni-
cillin, which cover the Clostridium species. If Vibrio infection is
suspected, the early use of tetracyclines (including doxycycline
and minocycline) and third-generation cephalosporins is crucial
for the survival of the patient, since these antibiotics have been
shown to reduce the mortality rate drastically (59).
Finally, type 4 NF can be treated with amphotericin B or
fluoroconazoles, but the results of this treatment are generally
disappointing.
As in every empirical antibiotic therapy, the dosage should be
tapered, based on the results of the initial blood, wound, and tissue
cultures, but continued until the infection is under control and for
at least 48 h after clinical and hemodynamic stabilization of the
patient has been achieved. Antibiotics should be administered for
up to 5 days after local signs and symptoms have resolved (62).
The mean duration of antibiotic therapy for NF is 4–6 weeks.
Intravenous immunoglobulin (IVIG) has recently been
described as a reasonable and desirable option for neutralizing
streptococcal toxins (63). There is evidence that a high dose of
IVIG may prove beneficial in severe streptococcal infections (64),
but this has yet to be demonstrated with randomized studies.
SURGICAL MANAGEMENT
Emergency surgical debridement of the affected tissues is the
primary management modality for NF. Surgical debridement,
necrosectomy, and fasciotomy are the main aspects of surgical
treatment. Surgical intervention is life-saving and must be per-
formed as early as possible, since a delay in treatment beyond
12 h in fulminant forms of NF can prove fatal. Surgical debride-
ment should be repeated during the next 24 h or later, depending
on the clinical course of the necrotizing infection and vital func-
tions. Many studies have pointed out that timing and the extent
of the first debridement are the most important risk factors in
terms of increased mortality rate. Mock et al. have shown that the
relative risk of death was 7.5 times greater in cases of restricted
primary debridement (65), whereas, other studies reported that
the mortality rate was nine times greater when primary surgery
was performed 24 h after the onset of symptoms (19).
Surgical management is indicated especially for patients dis-
playing intense pain and skin color change, such as edema and/or
ecchymoses, or signs of skin ischemia with blisters and bullae
(Figure 1). Patients must be operated on urgently when they
present with altered mental status, hypotension, an elevated band
formed in the differential WBC count, and metabolic acidosis.
These clinical and laboratory signs indicate that the patient has
developed SIRS or MODS, and the NF score has risen to phase 3.
The mortality rate in this phase is extremely high, reaching almost
70% (24).
Incisions are performed parallel to Langer’s lines to achieve
better surgical wound healing and less scarring. Surgery also min-
imizes the overall tissue loss as it inhibits infection spread to
the fascial plane, reducing the need for amputation (66). After
the release of pus and/or hemorrhagic fluid through incisions,
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FIGURE 1 |The excision of the necrotic tissues should extend until
healthy tissue is found, but should be limited to the edges of the
infection.
ventricle incisions are made, keeping the wound open in order to
allow drainage and to remove additional necrotic tissue.
Patients with NF should be closely monitored during the next
24 h; surgical wounds and tissue viability should be checked. Com-
plicated surgical wounds command a “second-look operation”
with radical surgical debridement. Patients with NF can require
from 5 up to 40 additional operations, depending on the timing
of the first surgical debridement, the adequacy of the primary
debridement and necrosectomy, signs of hemodynamic instabil-
ity, and concomitant illnesses, all of which are associated with
a high mortality rate (67). Evidence of hemodynamic instability
demands immediate resuscitation, transfer to an intensive care
unit, nutritional support, and enteral feeding.
The extent of tissue extracted depends on the body region,
which is infected. As a general rule, debridement will extend
until healthy tissue is found, though some authors recommend
that excision should be limited to the edges of infection (68).
The general consensus is that careful trimming of the potentially
salvageable soft tissue is also required (while non-infected skin
remains unattached) (Figure 1) (69).
Nutritional support is required from the first day of the patient’s
admission to hospital (preferably the ICU), to replace lost proteins
and fluid from large wounds and/or the resultant toxic shock.
Metabolic demands are similar to those of other major trauma or
burns, which means that the patient needs twice the basic caloric
requirements.
Necrotizing fasciitis of the abdominal wall requires special con-
sideration. Skin incision must be performed in the longitudinal
direction along the muscle-fascial layers of the inner abdominal
wall until healthy fascia is found. Parallel or ventricle incisions are
not performed because the bridges of skin and skin islands will
not usually survive. Postoperative management of abdominal wall
wounds involves serial dressing changes over the following days,
until the wound is free of recurrent or ongoing infection. The
use of a vacuum-assisted wound closing device (VAC) can also
be helpful. Aggressive surgical debridement should be repeated
in cases of infection progression across the deep fascial planes of
the abdominal wall. The extension of infection into the bowel,
resulting in bowel ischemia, bowel obstruction, and peritonitis, is
not an uncommon phenomenon. In such cases, an exploratory
laparotomy is needed to estimate the extent of infection inside the
abdominal wall. A radical surgical debridement at the site of infec-
tion and the retroperitoneal site is performed, followed by partial
bowel excision, depending on the part of the bowel (usually right
colon), which has been infected. A diverting colostomy is per-
formed with multiple drainages of the infected intra-abdominal
fluid collections. Surgical management of colonic perforation
complicated with peritonitis is a topic with considerable debate
in the literature. Hartmann’s resection has been considered the
procedure of choice in cases with diffuse peritonitis and remains
a safe technique for colectomy in a perforated colon, especially
in elderly patients with multiple co-morbidities. As concerns NF,
Hartmann’s resection is particularly preferred, since it allows time
for reconstruction of the abdominal wall defects, and the diverting
colostomy can be closed at a second stage. The primary defect on
the abdominal wall is usually large and is repaired with advanced
flaps using an abdominoplasty technique, biological mesh, or skin
grafts (70).
Fournier’s gangrene also requires special consideration. A pres-
sure sore, perineal abscess, or paraplegia frequently predispose
to the spread of infection into the scrotum, inguinal region, and
lower abdominal wall (Figure 2). An orchiectomy, cystostomy,
or diverting colostomy is often required dependent on whether
the infection has extended to the scrotum, perineal area, or lower
abdominal wall, respectively. Surgical management includes wide
tissue incision, radical debridement, and drainage of the areas
involved (71). The wound is washed with hydrogen peroxide,
saline, and 1% povidone iodine solution. Finally, it is covered
with occlusive and adsorptive dressing with antiseptic properties.
Again the use of VAC can accelerate the recovery period, pro-
viding clean surgical wounds. Once the patient is clinically and
hemodynamically stable, they can be submitted to reconstructive
surgery.
Necrotizing fasciitis of the extremities needs special consider-
ation. The extent of debridement is very important as additional
fasciotomies are needed in cases with compromised tissue viability
(67). The amount of tissue that needs to be excised is a contro-
versial issue, because the skin in the extremities usually appears
normal.
A study by Andreasen et al. showed that despite a normal exter-
nal appearance soft tissue in patients with NF has extensive vascu-
lar microthromboses as well as vasculitis. The risk of full-thickness
necrosis is high, and this can complicate a primary treated surgi-
cal wound (72). Consequently, it is recommended that clinicians
also remove healthy soft tissue, bearing in mind that extremities
showing NF may require amputation. The criteria for amputation
have been recommended by Tang et al. (73), the most significant
of which is extensive soft tissue necrosis with involvement of the
underlying muscles and rapidly progressing infection with a large
area of tissue necrosis. Other conditions that may justify ampu-
tation, are the presence of concurrent medical disease with high
anesthetic risk (ASA score III and above),and the presence of shock
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FIGURE 2 | A severe case of Fournier’s gangrene with excessive
erythema and edema in the perineal and gluteal regions as well as
skin necrosis with bullae.
(toxic or cardiogenic) requiring treatment with more than one
inotrope. Furthermore, concurrent vascular insufficiency further
increases the need for amputation, especially when the patient
is diabetic. Amputation is usually considered as a shorter proce-
dure associated with less blood loss than a radical debridement.
This explains why patients with hypotension and shock are best
treated with amputation, as they cannot endure additional pro-
tracted operations. Studies have proved that, although amputation
is not seen to reduce mortality, patients undergoing this procedure
required fewer repeat operations, which is extremely important for
patients presenting severe co-morbidities or a fulminant form of
NF (74).
Recent reports of NF of the axilla require special consideration.
A delay in surgical debridement can prove lethal, even more so than
an infection in a common site (75). Tissue in the axillary region
that is rich in blood vessels and lymphatics enables the infection to
spread rapidly to distant sites. The clinician should keep in mind
the need to avoid axillary contractures, after covering the exposed
neurovascular network (75). Again, surgical reconstruction of the
wound is essential for successful wound closure and should be
planned after clinical stabilization (76, 77).
USE OF VACUUM-ASSISTED CLOSURE DEVICE
Lately, many surgeons worldwide have started using vacuum-
assisted closure (VAC) therapy for fast and effective wound closure
FIGURE 3 | After surgical debridement, the use of the VAC system
helps wound healing by absorbing excess exudates; reducing localized
edema, and finally drawing wound edges together.
(78). Several studies in the general surgery, orthopedic, and gyne-
cological literature support the use of VAC devices. A VAC device
consists of a sterile, open-cell foam sponge that is placed in the
wound, the size of which is adjusted to the wound size. This
is covered with a transparent adhesive drape to create an air-
tight environment. The sponge is connected to a portable vacuum
pump by means of non-collapsible tubing. Evacuation is applied
to the sponge using the pump, which provides continuous negative
pressure. The VAC device improves wound healing by providing
microstrain (Figure 3). Several randomized studies have demon-
strated improved wound healing and a significant reduction of
wound surface area in full-thickness wounds treated with VAC
devices as compared to conventional gauze therapy (79).
The VAC dressing must be changed every 24–72 h. VAC ther-
apy has several benefits in wound management, with wound area
reduction and formation of granulation tissue being the most
prominent. Other benefits, such as effective wound cleaning and
the ability to remove the exudate render VAC a promising adjuvant
therapy for wound closure.
FUTURE THERAPIES
As a life-threatening condition, NF demands new management
strategies. Unfortunately, there are no single new therapies that
can manage NF; they all seem to play an assistive role. Undoubt-
edly, the use of VAC has many benefits in wound healing, and it
will be adopted by more physicians in the future.
A study by Anaya et al. (13) highlighted the role of IVIG in
the treatment of NSTI, especially if NSTI is associated with group
A streptococcal infection. The authors concluded that the use of
IVIG seemed rational in patients with group A streptococcal infec-
tion who developed streptococcal toxic shock syndrome and in
those with a high mortality risk (advanced age, hypotension, and
bacteremia). However, relevant studies investigating its use are
contentious and difficult to compare because of the small number
of patients and the different methodologies used.
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An interesting study by Lu et al. (80) showed that kallistatin,
originally found to be a tissue kallikrein-binding protein, can
increase the survival of group A streptococcus infected mice. The
researchers concluded that kallistatin significantly increased the
survival rate of GAS-infected mice, and also reduced local skin
damage and bacterial counts. Moreover, its use improved infiltrat-
ing cell viability in the local infection site, as well as bacterial clear-
ance activity of immune cells (81). The efficiency of intracellular
bacterial killing in neutrophils was directly enhanced by kallistatin
administration. Several inflammatory cytokines, including tumor
necrosis factor alpha, interleukin 1β, and interleukin 6, in local
infection sites were reduced by kallistatin. Furthermore, kallis-
tatin treatment was reported to reduce vessel leakage, bacteremia,
and liver pathology after local infection. However, further studies
are warranted before safe conclusions can be drawn concerning its
use in gas-forming infections, such as NF (82).
CONCLUSION
Necrotizing fasciitis is a rare but life-threatening condition, with a
high mortality rate (median mortality 32.2%) that approaches
100% without treatment. Numerous conditions are associated
with this pathology, such as diabetes mellitus, immunosuppres-
sion, chronic alcohol disease, chronic renal failure, and liver cir-
rhosis, which can be conductive to the rapid spread of necrosis, and
increase in the mortality rate. The diagnosis of NF is difficult and
the differential diagnosis between NF and other necrotizing soft
tissue infections more so. However, the clinician should do their
utmost to secure the diagnosis of NF, as a delay in diagnosis can be
fatal, and septic shock is inevitable if the disease remains untreated.
The characteristic of NF is the clinical status change over time.
The early clinical picture includes erythema, swelling, tenderness
to palpation, and local warmth; once the infection develops, the
infection site presents skin ischemia with blisters and bullae. The
diagnosis of NF can be secured faster with the use of laboratory-
based scoring systems, such as the LRINEC score or the FGSI score,
especially in cases of Fournier’s gangrene. However, the diagnosis
is definitely established by performing explorative surgery at the
infected site.
Management of the infection begins with antibiotic treat-
ment. In the majority of cases with NF (70–90%) the reasonable
pathogens are two or more, suggesting the use of broad-spectrum
antibiotics. The value of antibiotic treatment in NF is relatively low,
and early and aggressive drainage and debridement is required. In
NF of the extremities, the clinician should consider amputating
the infected limb, although this will not reduce the risk of mor-
tality. Finally, postoperative management of the surgical wound
is important, along with proper nutrition of the patient. The use
of VAC therapy in wound management has greatly improved the
results of postoperative management.
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